Publications by authors named "Ingo Hartung"

Claim this Profile
I
Introduction to the themed collection on 'Induced-Proximity Pharmacology'.
Ingo V Hartung, Lindsey I James, Lyn H Jones

RSC Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead.
Jean Quancard, Anders Bach, Chiara Borsari, Russell Craft, Christian Gnamm, Ingo V Hartung

ChemMedChem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Workflow for E3 Ligase Ligand Validation for PROTAC Development.
Nebojša Miletić, Janik Weckesser, Thorsten Mosler, Rajeshwari Rathore, Marina E Hoffmann, Ingo V Hartung

ACS Chem Biol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran -Active KAT6AB Inhibitor.
Antonius Ter Laak, Roman C Hillig, Steven J Ferrara, Daniel Korr, Naomi Barak, Ingo V Hartung

J Med Chem· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.
Jeffrey Mowat, Rafael Carretero, Gabriele Leder, Nuria Aiguabella Font, Roland Neuhaus, Ingo V Hartung

J Med Chem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition.
Lilia Falkenstern, Victoria Georgi, Stefanie Bunse, Volker Badock, Manfred Husemann, Ingo V Hartung

Sci Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The experiment is the limit.
Christina E M Schindler, Daniel Kuhn, Ingo V Hartung

Nat Rev Chem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Christina Kober, Julian Roewe, Norbert Schmees, Lars Roese, Ulrike Roehn, Ingo V Hartung

J Immunother Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.
Frank Wunder, Johannes-Peter Stasch, Andreas Knorr, Thomas Mondritzki, Damian Brockschnieder, Ingo V Hartung

Br J Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation.
Mary M Mader, Joachim Rudolph, Ingo V Hartung, David Uehling, Paul Workman

Cancer Discov· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 17 EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders.
Alessio Ciulli, Suzanne O'Connor, Chun-Wa Chung, Ingo V Hartung, Andrea Testa

ChemMedChem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.
Amjad Ali, Marcus Bauser, Sophie Bertrand, Wesley Blackaby, Christoph Boss, Ingo V Hartung

ChemMedChem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes.
Ingo V Hartung, Joachim Rudolph, Mary M Mader, Monique P C Mulder, Paul Workman

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
Alexandros Vakalopoulos, Frank Wunder, Ingo V Hartung, Gorden Redlich, Rolf Jautelat

J Med Chem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target 2035 - an update on private sector contributions.
Suzanne Ackloo, Albert A Antolin, Jose Manuel Bartolome, Hartmut Beck, Alex Bullock, Ingo V Hartung

RSC Med Chem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation.
Jean Quancard, Anna Vulpetti, Anders Bach, Brian Cox, Stéphanie M Guéret, Ingo V Hartung

ChemMedChem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design.
Johannes Krieger, Fiona J Sorrell, Ansgar A Wegener, Birgitta Leuthner, Fouzia Machrouhi-Porcher, Ingo V Hartung

ChemMedChem· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rules were made to be broken.
Ingo V Hartung, Bayard R Huck, Alejandro Crespo

Nat Rev Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target 2035 - update on the quest for a probe for every protein.
Susanne Müller, Suzanne Ackloo, Arij Al Chawaf, Bissan Al-Lazikani, Albert Antolin, Ingo V Hartung

RSC Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Stefan Gradl, Holger Steuber, Joerg Weiske, Magda M Szewczyk, Norbert Schmees, Ingo V Hartung

SLAS Discov· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No shortcuts to SARS-CoV-2 antivirals.
Aled Edwards, Ingo V Hartung

Science· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery.
Jean Quancard, Anders Bach, Brian Cox, Russell Craft, Dirk Finsinger, Ingo V Hartung

ChemMedChem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics*.
Mathew Sutherland, Alice Li, Anissa Kaghad, Dimitrios Panagopoulos, Fengling Li, Ingo V Hartung

ChemMedChem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes.
Jean Quancard, Brian Cox, Dirk Finsinger, Stéphanie M Guéret, Ingo V Hartung

ChemMedChem· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donated chemical probes for open science.
Susanne Müller, Suzanne Ackloo, Cheryl H Arrowsmith, Marcus Bauser, Jeremy L Baryza, Ingo V Hartung

Elife· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis